Stay updated with breaking news from Seemaa Khan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.
Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.
Patients with early breast cancer and negative ultrasound axillary lymph node staging had similar locoregional relapse and distant DFS at 5 years whether or not they received SLN biopsy.